Hypercalcemia at diagnosis of diffuse large B-cell lymphoma is not uncommon and is associated with high-risk features and a short diagnosis-to-treatment interval.
Adult
Aged
Aged, 80 and over
Female
Follow-Up Studies
France
/ epidemiology
Humans
Hypercalcemia
/ epidemiology
Lymphoma, Large B-Cell, Diffuse
/ complications
Male
Middle Aged
Prevalence
Prognosis
Retrospective Studies
Risk Factors
Survival Rate
Time-to-Treatment
/ statistics & numerical data
Young Adult
diagnosis-to-treatment interval
diffuse large B-cell lymphoma
high-risk features
hypercalcemia
prevalence
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
21
11
2019
revised:
11
02
2020
accepted:
08
03
2020
pubmed:
10
4
2020
medline:
1
9
2020
entrez:
10
4
2020
Statut:
ppublish
Résumé
Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin lymphoma. The prevalence of hypercalcemia in this neoplasm and its prognostic significance is unclear. We retrospectively evaluated the prevalence of hypercalcemia at diagnosis of DLBCL and explored associations of hypercalcemia with clinical factors and outcome. Outcome was assessed using event-free survival at 24 months (EFS24). A total of 305 patients (248 de novo DLBCL and 57 transformed indolent lymphomas) diagnosed between 2006 and 2018 in Reims were analyzed. The prevalence of calcemia >10.5 mg/dL at diagnosis of de novo DLBCL and transformed indolent lymphomas was 23% and 26%, respectively. Hypercalcemia in de novo DLBCL was strongly associated with high-risk features, especially with International Prognostic Index (IPI) components, but also with B symptoms, β2-microglobulin, hemoglobin, and albumin levels. The diagnosis-to-treatment interval was significantly shorter for hypercalcemic patients (P = .001). These associations with adverse prognostic factors translated into lower rates of EFS24 (HR = 1.66; 95% CI, 1.08-2.54) and shorter PFS (P = .0059) and OS (P = .0003) for patients with lymphoma-related hypercalcemia but not independently of IPI parameters. These data suggest that hypercalcemia is rather a biomarker of the underlying biological aggressiveness of DLBCL.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
326-333Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues (Revised 4th Edition). Lyon, France: International Agency for Research on Cancer; 2017:585.
Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242.
Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera international trial (MInT) group. Lancet Oncol. 2006;7(5):379-391.
Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116(12):2040-2045.
International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-994.
Bairey O, Shacham-Abulafia A, Shpilberg O, Gurion R. Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor. Hematol Oncol. 2016;34(4):184-192.
Montalbán C, Díaz-López A, Dlouhy I, et al. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β2-microglobulin yields a more accurate GELTAMO-IPI. Br J Haematol. 2017;176(6):918-928.
Troppan KT, Melchardt T, Deutsch A, et al. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients. Eur J Haematol. 2015;95(6):538-544.
Goldner W. Cancer-related hypercalcemia. J Oncol Pract. 2016;12(5):426-432.
Shallis RM, Rome RS, Reagan JL. Mechanisms of hypercalcemia in non-Hodgkin lymphoma and associated outcomes: a retrospective review. Clin Lymphoma Myeloma Leuk. 2018;18(2):e123-e129.
Abadi U, Peled L, Gurion R, et al. Prevalence and clinical significance of hypercalcemia at diagnosis in diffuse large B-cell lymphoma. Leuk Lymphoma. 2019;60(12):2922-2926.
Laurent C, Baron M, Amara N, et al. Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath network. J Clin Oncol. 2017;35(18):2008-2017.
Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282.
Canellos GP. Hypercalcemia in malignant lymphoma and leukemia. Ann N Y Acad Sci. 1974;230:240-246.
Baechler R, Sauter C, Honegger HP, Oelz O. Hypercalcemia in non-Hodgkin lymphoma. Schweiz Med Wochenschr. 1985;115(10):332-334.
Majumdar G. Incidence and prognostic significance of hypercalcaemia in B-cell non-Hodgkin's lymphoma. J Clin Pathol. 2002;55(8):637-638.
Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(32):5165-5169.
Watanabe N, Yasuda H, Morishita S, et al. Richter's syndrome with hypercalcemia induced by tumor-associated production of parathyroid hormone-related peptide. Case Rep Oncol. 2017;10(1):123-126.
Beaudreuil J, Lortholary O, Martin A, et al. Hypercalcemia may indicate Richter's syndrome: report of four cases and review. Cancer. 1997;79(6):1211-1215.
Durot E, Tomowiak C, Michallet A-S, et al. Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French innovative leukemia organization (FILO). Br J Haematol. 2017;179(3):439-448.
Maurer MJ, Ghesquières H, Link BK, et al. Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials. J Clin Oncol. 2018;36(16):1603-1610.
Camus V, Dubois S, Jardin F, Tilly H. Prognostic impact of diagnosis to treatment interval (DTI) in diffuse large B-cell lymphoma patients: a real-life monocentric study. Leuk Lymphoma. 2019;60(3):839-841.
Maletkovic J, Isorena JP, Palma Diaz MF, Korenman SG, Yeh MW. Multifactorial hypercalcemia and literature review on primary hyperparathyroidism associated with lymphoma. Case Rep Endocrinol. 2014;2014:893134.